Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433544 | 1.00 | ABCC4 (0.61) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL6598298 | 0.85 | HCAR2 (0.47) | MEN1KMT2ASLC6A2SLC6A3HCAR2 | |
| SCHEMBL1177086 | 0.85 | CA2 (0.48) | LMNAMEN1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL15962296 | 0.85 | CA12 (0.48) | MEN1KMT2ASLC6A2SLC6A3HCAR2 | |
| SCHEMBL20888605 | 0.85 | HCAR2 (0.47) | MEN1KMT2ASLC6A2SLC6A3HCAR2 | |
| SCHEMBL5309049 | 0.83 | FFAR1 (0.64) | HCAR2FFAR1FAAHCES1 | |
| SCHEMBL4688780 | 0.82 | FFAR1 (0.60) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL16361002 | 0.81 | HPGDS (0.54) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL29562628 | 0.81 | HPGDS (0.54) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL20888574 | 0.81 | CA12 (0.57) | MEN1KMT2ASLC6A2SLC6A3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116804007-A | Prinsene Li Wei free base hemihydrate, method for the production and use thereof | 艾库里斯有限及两合公司 | 2023-09-26 | — | — | CN | claimed |
| CN-109996798-B | N- [5- (aminosulfonyl) -4-methyl-1, 3-thiazol-2-yl ] -N-methyl-2- [4- (2-pyridyl) -phenyl ] -acetamide free base hemihydrate, its preparation method and use | 艾库里斯有限及两合公司 | 2023-05-05 | — | — | CN | claimed |
| EP-3544976-B1 | N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)-PHENYL]-ACETAMIDE FREE BASE HEMIHYDRATE, METHODS OF MANUFACTURE AND USES THEREOF | AICURIS GMBH & CO KG (DE) | 2021-02-17 | — | — | EP | claimed |
| US-9340535-B2 | N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | AICURIS GMBH & CO. KG (DE) | 2016-05-17 | — | — | US | claimed |
| US-20140221433-A1 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | AICURIS GMBH & CO. KG (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2598501-B1 | N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE MESYLATE MONOHYDRATE | AICURIS GMBH & CO KG (DE) | 2014-03-12 | — | — | EP | claimed |
| EP-2598501-A1 | N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE MESYLATE MONOHYDRATE | AiCuris GmbH & Co. KG (DE) | 2013-06-05 | — | — | EP | claimed |
| WO-2013045479-A1 | N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE MESYLATE MONOHYDRATE | AICURIS GMBH & CO. KG (DE) | 2013-04-04 | — | — | WO | claimed |
| EP-2573086-A1 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | AiCuris GmbH & Co. KG (DE) | 2013-03-27 | — | — | EP | claimed |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260070900-A1 | A NOVEL CRYSTALLINE FORM OF PRITELIVIR | ASSEMBLY BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | INNOVATIVE MOLECULES GMBH (DE) | 2026-01-20 | — | — | US | disclosed |
| EP-4580601-A1 | PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4581031-A1 | A NOVEL CRYSTALLINE FORM OF PRITELIVIR | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-1401436-A1 | THIAZOLYL AMIDES AND THEIR USE AS ANTIVIRAL DRUGS | Bayer HealthCare AG (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20040006076-A1 | Thiazolyl amide derivatives | AICURIS GMBH & CO. KG (DE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003007946-A1 | SECONDARY 1,3-THIAZOLE-5-YL SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003000260-A1 | THIAZOLYL AMIDES AND THEIR USE AS ANTIVIRAL DRUGS | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| EP-1244641-A1 | THIAZOLYL AMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047904-A1 | THIAZOLYL AMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221433-A1 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate | BPNT1, BOLA2; BOLA2B, NAT1 | ABCC4 893/4885LMNA 763/4885GAA 2603/4885 |
| US-20040006076-A1 | Thiazolyl amide derivatives | MAVS, EIF2AK2, SARS1 | ABCC4 1199/4885LMNA 3230/4885GAA 158/4885 |
| US-20260070900-A1 | A NOVEL CRYSTALLINE FORM OF PRITELIVIR | TK1, POLL, GSK3A | ABCC4 755/4885LMNA 785/4885GAA 108/4885 |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | CA2, CA6, HCFC1 | ABCC4 4148/4885LMNA 3543/4885GAA 89/4885 |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | IFNAR1, CCR10, EIF2AK2 | ABCC4 1766/4885LMNA 1706/4885GAA 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.